sibi, btrn...
why, I recognize those symbols, heheh.
I guess there was nothing said during the
medi presentation at H&Q...there was even
less volume changing hands than usual on
Tuesday in BioTransplant, a mere 3200 shrares
for pete's sake. Maybe next conference...
The data from this trial are currently being
analyzed. The results of this trial are expected
to be presented at a medical conference in 1999.
biz.yahoo.com
I checked the medi thread on Yahoo, the consensus
there is that AT&T is interesting...hmmm, I thought
the @home TCI merger was about bandwidth, not GvHD,
haha.
Well, your picks aren't doing any worse than mine,
you could say that I stumbled across what looked
like a mighty sequoia...and the damn thing fell on
my head...and nobody heard it.
You said...Let's get loud and defeat such arrogance.
You are welcome to convince me to add or drop a company
from the portfolio. I will give it a shot.
Cambridge NeuroScience
I was buying cnsi all the way down from it's spike
last month, ooof. I think I found two new
cnsi patents on the IBM server, I can get a couple
numbers, but no text yet. Anyway, submitted for your
approval, rhGGF2...
...the Cambridge Neuroscience ggf url:
cambneuro.com
The manufacture of purified recombinant human Glial Growth Factor 2 (rhGGF2) for use in efficacy studies has been very successful. We have scaled up the expression and purification processes, and gram quantities of the compound are already available. Cambridge NeuroScience has a strong proprietary position. The U.S. Patent Office has allowed several key claims related to the DNA and protein sequences of rhGGF2 as well as methods of its use in the treatment of several disorders, validating Cambridge NeuroScience's exclusive right to commercialize the factor.
The partner who covers the burn...
biz.yahoo.com
Cambridge NeuroScience and its academic collaborators
have generated impressive data demonstrating the unique
mechanism by which GGF2 stimulates the remyelination of
nerve cells, said David Lowe, Ph.D., head of CNS research
at Bayer. The companies have worked together in developing
a manufacturing process for the molecule.
...and the gaggle of Leads
recap.com
some cancer, nerve regeneration, multiple sclerosis,
myasthenia gravis, peripheral neuropathies, muscle
wasting, muscle injury, spinal cord injuries,
muscular dystrophies, and diabetic and chemo-induced
neuropathies.
Okay, it is only a seedling so far...but
Could be the biggest damn tree in the forest someday!
I will call it, gasp, an investment.
Mike, knowing no fear, has made his cnsi position
twice the size of his ctic and ntii positions...
thrice the size of his sibi, btrn, ctii, and aria
positions...
...and many times larger than his small investments
in tgen and xoma.
--Mike
|
